

September 13-14, 2002 | Tartu, Estonia

ystematic advances in biomedical research enabled by genomics are expected to revolutionize medicine in the near future. Differences in individual genomes cause responses to drugs to vary considerably - "one size fits all" drug is not possible. The best strategy to discover the genetic basis for variation in health among human beings is through analysis of sequence variation in DNA.

Estonia is about to do just that. The Estonian Genome Project (www.geenivaramu.ee) has been launched in a clearly defined ethical and legal environment. The project aims to phenotype and genotype approximately 1 million individuals in Estonia. The genotype-phenotype database to be completed will serve as a valuable tool in population based post-genomic database driven drug discovery.

PARTICIPATION FEE:	EUR
BY JUNE 25, 2002 Commercial Academic	
BY SEPTEMBER 5, 2002 Commercial Academic	

Further details about the provisional programme, exhibition and registration at www.geneforum.ee Deadline for submission of abstracts for poster session is August 1, 2002

GENE TECHNOLOGY FORUM 2002 WILL FOCUS ON:

GENETICS, GENOMICS AND DISEASES GENETIC INFORMATION AND NEW ECONOMY **GENETICS AND BIOETHICS** ESTONIAN GENOME PROJECT

CONFIRMED SPEAKERS:

Prof. ANNE-LISE BØRRESEN-DALE. Institute for Cancer Research, The Norwegian Radium Hospital, Norway

Dr. PAOLO BOFFETTA, International Agency for Research on Cancer, France

Dr. MICHAEL D. CALDWELL, Marshfield Medical Research Foundation, USA

Prof. DETLEV GANTEN, Max-Delbrück Centre of Molecular Medicine, Germany

Prof. MARK LATHROP, Centre National de Genotypage, France

Prof. ALEXANDRE MAURON, University of Geneva, Switzerland

Prof. ANDRES METSPALU, University of Tartu, Estonia

Prof. BRIGITTE FEUILLET-LE MINTIER, Rennes University, France

Prof. AARNO PALOTIE, Department of Pathology and Laboratory Medicine, UCLA, USA

Prof. LEENA PELTONEN, Department of Human Genetics, UCLA, USA

Prof. IVAR ROOTS, Institute of Clinical Pharmacology, Charité Clinics, Germany

Prof. ERWIN SCHURR, McGill University, Canada

Prof. MATHIAS UHLEN, The Royal Institute of Technology, Sweden

Dr. DAVID WANG, First Genetic Trust Inc., USA



